Huma builds regulated Software as a Medical Device (SaMD) solutions
Building a SaMD is complex. Launching it across several continents is even more challenging, but the hardest part is scaling and sustaining it across thousands of hospitals, clinics and patients. When you see our technology, infrastructure and innovation in operation, you will understand why some of the world's biggest life science companies have chosen to use Huma.
Talk to us
Winner of the 2022 Prix Galien International award for digital health, 'pharma's Nobel prize'1
Active users across
our platforms2
Adherence and retention rates across our care and research deployments3
Devices have been shipped in support of our projects2
Hospitals and clinics use our technologies to make sustainable impacts for patients2
Huma's digital-first health platforms support a network of 27m patients2
Transforming
healthcare
Registered and able to immediately place products in 33 countries.
Capable of supporting all language requirements.
Self-service modular platform to enable rapid configuration.

"The Most Important Healthcare Design of 2021" by Fast Company
Industry-leading and flexible IoMT integration
We are certified under ISO 27001, Cyber Essentials Plus and we are 21 CFR and GxP compliant
Cloud-agnostic platform that can run on any system
Can be deployed across multiple therapeutic areas
Orthopaedics,
Diabetes, Heart
health
Connect with us and our partners
We have successfully deployed some of the largest SaMD solutions across multiple patient populations, including heart failure, cardio metabolic disease, pulmonary hypertension and more.
Compliance built-in
EU MDD & MDR
ISO13485
ISO27001
21CFR820 US FDA Class I exempt
IEC/ISO62304
IEC 82304-1
ISO14971
ISO14155
IEC62366

CyberEssentials

CyberEssentials Plus

Approved Pharma Supplier
Regulatory Intelligence
Global Regulatory Footprint
World-leading healthcare
companies partner
with Huma


Talk to us

Sources
1. Winner of the 2022 Prix Galien International and 2021 Prix Galien USA awards for digital health https://huma.com/announcement/huma-prix-galien-2022
2. Based on internal data, correct as of June 2022
3. Range of data from across a number of Huma projects
4. The telemedicine and call centre functionality is used through the app but is not part of the medical device.
5. https://www.nhsx.nhs.uk/covid-19-response... The full report is available on request.
6. Data from 2021 pilot study. Full evaluation of the service is in preparation
7. Dolezalova, N et al. (2021) Development of an accessible 10-year Digital CArdioVAscular (DiCAVA) risk assessment: a UK Biobank study, European Heart Journal Digital Health https://doi.org/10.1093/ehjdh/ztab057
8. Publication in production